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With Stable Coronary Artery Disease
Undergoing Ad Hoc Percutaneous
Coronary Intervention*
Dominick J. Angiolillo, MD, PHD, Francesco Franchi, MDI n patients undergoing percutaneous coronaryintervention (PCI), pre-treatment with a P2Y12 re-ceptor inhibitor has been for years advocated as
a strategy to protect from periprocedural thrombotic
events (1). However, most recently, the need for
pre-treatment before diagnostic angiography has
been largely debated, particularly in patients with
stable coronary artery disease (CAD) (1,2). Accord-
ingly, although practice guidelines have traditionally
advocated the importance of early initiation of P2Y12-
inhibiting therapies in patients undergoing PCI, most
recent guidelines provide less emphasis on timing
of initiation of treatment (1). Nevertheless, effective
levels of P2Y12 receptor blockade reduce ischemic
events in the vulnerable peri-PCI period (3). However,
systematic upstream administration of a P2Y12 recep-
tor inhibitor in all patients going to the catheteriza-
tion laboratory inevitably leads to unnecessary
treatment of those who do not require PCI; moreover,
this can also increase the risk of hemorrhagic com-
plications and prolong hospitalization in patients
requiring surgical revascularization (1).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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contents of this paper to disclose.Clopidogrel is still the most widely used P2Y12 re-
ceptor inhibitor and is the only agent of this class
approved for patients with stable CAD undergoing PCI
(4). However, it is well-established that the pharma-
codynamic (PD) response proﬁles of clopidogrel are
delayed and subject to variability. Most importantly,
patients with high on-treatment platelet reactivity
(HPR) have an increased risk of ischemic events,
in particular stent thrombosis (5). The shorter time
frames from clinical presentation to the catheteriza-
tion laboratory, the development of antiplatelet
therapies with more prompt and potent effects, and
the fact that most elective PCIs are performed on an
ad hoc basis (immediately after diagnostic coronary
angiography) have further questioned the need for
pre-treatment with P2Y12 receptor inhibitors (1).
However, there is limited experience with the new-
generation oral P2Y12 receptor inhibitors (i.e., prasu-
grel and ticagrelor) in non-acute coronary syndrome
(ACS) settings. Although it may also be argued that
peri-PCI thrombotic events are less likely to occur
in non-ACS patients, clinical investigations with
the potent intravenous P2Y12 receptor antagonist
cangrelor showed a signiﬁcant reduction in early
thrombotic events after PCI, including in patients
with stable CAD, highlighting the clinical beneﬁts of
peri-interventional reduction of platelet reactivity
(3). Importantly, peri-PCI thrombotic events are
known to be related to long-term adverse ischemic
outcomes, including mortality (6).SEE PAGE 219In this issue of JACC: Cardiovascular Interventions,
Hochholzer et al. (7) report the results of a study
investigating the PD effects of prasugrel loading
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229dose (LD) in patients with stabilized CAD undergo-
ing elective PCI not pre-treated with a P2Y12 re-
ceptor inhibitor. Patients (n ¼ 300) were randomly
assigned to receive a LD of either prasugrel 60 mg,
prasugrel 30 mg, or clopidogrel 600 mg immediately
before PCI, after deﬁning coronary anatomy. A
cohort of pre-treated patients (n ¼ 100) was
included in a registry. ADP-induced platelet aggre-
gation was measured at baseline and 30, 60, 90, 120
min and 24 h after LD using the Multiplate Analyzer
(Roche Diagnostics, Mannheim, Germany). The au-
thors found that at 60 min following LD, prasugrel
60 mg led to a signiﬁcant reduction in HPR ($468
arbitrary aggregation units  min) rates compared
with clopidogrel 600 mg (33% vs. 55%; p < 0.001;
primary endpoint). The reduction in HPR rates with
prasugrel 60 mg was already evident at 30 min and
maintained up to 2 h. Prasugrel 30 mg exerted in-
termediate effects, with lower incidence of HPR
than clopidogrel only at 30 and 60 min following
LD. Overall, platelet inhibition achieved by prasu-
grel 60 mg at 1 h post-LD was achieved by clopi-
dogrel 600 mg only 2 h post-LD. Differences
between treatments were no longer evident at 24 h.
Of note, HPR rates and levels of platelet reactivity
achieved by prasugrel 60 mg at 2 h post-LD were
lower than those of the cohort of patients pre-
treated with clopidogrel included in the registry.
In an exploratory analysis, clinical outcomes at
30 days, including bleeding and ischemic events,
were low and similar between groups, although a
numerical increase in minor bleeding was noted in
the prasugrel 30-mg group (7).
The major strength of this study is that this is the
ﬁrst to prospectively assess the effects of prasugrel
LD, administered after coronary angiography, in pa-
tients with stable CAD undergoing ad hoc PCI,
showing a remarkable reduction in HPR rates and
platelet reactivity. These results are overall antici-
pated because of the known pharmacological proﬁle
of prasugrel (4), and are in line with another study of
CAD patients in stable condition, but who were pre-
treated with either prasugrel 60 mg or clopidogrel
600 mg (8). The results of this investigation are also
in line with a recent study comparing the PD effects
of ticagrelor versus clopidogrel in low-risk troponin-
negative ACS patients undergoing ad hoc PCI (9).
Although the current investigation was not
designed to assess the clinical impact of this
approach, the authors provide informative PD data
(i.e., HPR rates) that in larger investigations have
shown to be associated with thrombotic events (5).
In line with the observations made above, in
this study, less than one-half of patients undergoingcoronary angiography ultimately underwent PCI.
This observation further underscores how in real-
world clinical practice routine pre-treatment with a
P2Y12 receptor inhibitor among patients going to the
catheterization laboratory exposes a high number of
patients to unnecessary treatment, which can
potentially be a bleeding hazard. This issue is
noteworthy considering the low “threshold” to send
patients to the catheterization laboratory, particu-
larly in the United States, where 20% to 40% of
patients undergoing elective angiography were
found to have angiographically normal coronary ar-
teries, w50% with obstructive disease, and only 25%
receiving PCI (10).
Several considerations need to be made in order to
correctly interpret the ﬁndings of this study. First,
the authors used only 1 platelet function assay.
Indeed, the use of other assays would have been
useful to conﬁrm the consistency of study results.
Second, the authors did not include a group of
patients randomized to pre-treatment with clopi-
dogrel before coronary angiography. This would have
allowed deﬁning whether in-laboratory use of pra-
sugrel provides greater peri-PCI platelet inhibition
than clopidogrel pre-treatment. Although this might
be assumed from the data of patients included in the
registry of this study, these patients had signiﬁcantly
different baseline characteristics than those who
were randomized, which makes it difﬁcult to make
any meaningful comparisons. Third, the study was
not powered for clinical endpoints. Therefore, no
ascertainments on the safety and efﬁcacy of this
approach can be made, and the absence of increased
bleeding with prasugrel needs to be interpreted with
caution. Accordingly, whether the use of a lower LD
of prasugrel (i.e., 30 mg) may represent a favorable
strategy to balance thrombotic and bleeding risk
is unknown. Finally, the authors did not explore
the PD effects of switching from prasugrel to clopi-
dogrel. In fact, understanding optimal timing and
dosing of clopidogrel administration when switching
from the new-generation oral P2Y12 receptor antago-
nists remains an important conundrum in clinical
practice (11).
Deﬁning the best antiplatelet approach in P2Y12
receptor antagonist naive patients undergoing ad hoc
PCI is a topic of debate. The study by Hochholzer et al.
(7) provides important PD data showing that a LD of
prasugrel achieves prompt, potent, and predictable
antiplatelet effects in the peri-PCI period among CAD
patients in stable condition. However, the clinical
impact of this strategy needs to be deﬁned in studies
adequately powered for safety and efﬁcacy. More-
over, how such strategy of using in-lab treatment
Angiolillo and Franchi J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6
Prasugrel in Stable CAD F E B R U A R Y 8 , 2 0 1 6 : 2 2 8 – 3 0
230with a new generation oral P2Y12 inhibitor in non-ACS
settings compares with cangrelor is currently un-
known. Indeed, the greater practicality and lower
costs associated with an oral agent would make this
an attractive treatment option, but would warrant
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